|
|
|
Vessel Closure
|
Cath Lab Digest contains numerous articles on all types of vessel closure procedures, including manual compression, mechanical compression, PADS, as well as suture based and collagen based vessel closure. For more information, see our articles below. |
|
June 2004
Next Generation Suture-Mediated Vessel Closure System Abbott Vascular Devices, a division of Abbott Laboratories, announced the launch of the next generation Perclose® suture-mediated vessel closure system, Perclose ProGlide? Microsurgical Dilatation Device Boston Scientific Corp. announced the results from the Cutting EDGE clinical trial for its Peripheral Cutting Balloon Device. Mr. Sheridan founded or helped found four major medical catheter companies: United States Catheter and ...
|
Clinical and Industry News
Many physicians had considered tying the knot the most difficult step of Abbott Vascular Devices? ? Medical schools have always used anatomical samples as teaching tools.
|
Clinical and Industry News
Clinical and Industry News Industry News: Clinical and Industry News - Lifestyle Changes Can Quickly Reverse Heart Risks In less than a month, individuals can reverse serious heart disease risk factors by making significant lifestyle changes, researchers are reporting. Amiodarone plus beta-blocker significantly reduced (73 percent) the risk of shock compared with beta-blocker alone and sotalol (57 percent reduction). The researchers found that sibling CVD was associated with a 55 percent ...
|
Clinical and Industry News
The study? ? Specific results included: ?
|
CLINICAL AND INDUSTRY NEWS
? Reduce cath lab workload ? Contain inventory costs ?
|
Just a Reminder: There is a Patient Under Those Drapes!
- Heidi Bonneau, RN, MS, CCA Highlands Consulting, Inc. San Jose, California Having a cardiovascular procedure is often a life-changing event for the patient and family. The cath lab environment is completely foreign to the patient and family, with equipment, sounds, hustle and bustle, as well as everyday procedures. Cath Lab Digest - ISSN: 1073-2667 - Volume 14 - Issue 03 (March 2006) - March 2006 - Pages: 63 - 63 Just a Reminder: There is a Patient Under Those Drapes!
|
Emerging Concepts in the Response to Antiplatelet Therapy
Platelet activation and aggregation is essential for the formation of thrombus, which normally represents a beneficial, hemostatic process after vascular injury (for example, after the removal of a femoral artery sheath using manual compression.)
|
Primary Angioplasty at Community Hospitals in the 21st Century Now The Treatment of Choice for Myocardial Infarction at Qualified Hospitals Without Cardiac Surgery
It was 2 am the night after Thanksgiving. John went into the bathroom to try to relieve his chest pain. He vomited copious amounts of bloody coffee-ground material and passed out. His wife awakened hearing his fall. She found John on the floor and called 911 immediately. John was brought to the local emergency department (ED) in the nearby community hospital, obtunded, white, cold and clammy with a systolic pressure of 80 mmHg and with ?tombstone? ST elevation indicating a large infero-apical-lateral myocardial infarction (MI) on EKG. His pajama shirt was covered with bloody vomitus.
|
Is it Time for Qualified Community Hospitals to Consider Non-Emergent Coronary Intervention without Cardiac Surgery?
While on vacation with his wife, William could no longer ignore the waxing and waning pressure he felt in his chest while driving through New Hampshire. He presented to Exeter Hospital?s emergency department [ED] for evaluation. In the ED, he was pain-free. His physical exam revealed a BP 183/113, heart rate 103, no neck vein distention, clear lungs, and an S4 gallop. Chest x-ray within normal limits. His electrocardiogram (EKG) was unremarkable (Figure 1, upper panel). Cardiac enzymes were elevated: troponin I 4.0, CPK MB 8.5. William, a 59 year-old computer programmer, had hypertension, dyslipidemia (later fasting triglycerides of 926 and glucose 99 were noted), obesity, and a family history of premature coronary disease.
|
The TENACITY Trial
Studying a higher bolus dose of tirofiban than in TARGET, this large-scale, randomized trial includes abciximab, and combines each IIb/IIIa inhibitor with either bivalirudin or heparin.
|
|
|
|
|
|
|
|
On Demand Medical Education
|
|
|
|
|
